Areas of Focus
- Development of small molecule anti-tumor drugs
Work Experience
- 2019-09 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
- 2014-11 to 2019-09 - University of Michigan - Postdoctoral Researcher
- 2009-09 to 2014-07 - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - PhD Student
- 2005-09 to 2009-07 - Nanchang University - Undergraduate
Academic Background & Achievements
- 2009-09 to 2014-07 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- 2005-09 to 2009-07 Bachelor's: Nanchang University
Publications
- Discovery of a PROTAC degrader for METTL3-METTL14 complex, 13th Author, 2024
- Discovery of a potent and selective covalent threonine tyrosine kinase (TTK) inhibitor, 11th Author, 2024
- Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy, 9th Author, 2023
- Discovery of 7H-Pyrrolo2,3-dpyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors, 10th Author, 2023
- Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase, 11th Author, 2022
- Structure-Based of a Series of NSD2-PWWP1 Inhibitors, 11th Author, 2022
- Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression, 3rd Author, 2021
- Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation, 10th Author, 2021
- Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation, 7th Author, 2021
- Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor, 11th Author, 2021
- Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity, 1st Author, 2020
- Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, 4th Author, 2019
- Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases, 2nd Author, 2019
- Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, 1st Author, 2018
- Design and optimization of small molecule inhibitors blocking the menin-MLL interaction, 2nd Author, 2017
- Structure-based design of small-molecular inhibitors targeting the Menin-MLL protein-protein interaction, 1st Author, 2017
- 1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor gamma and promote the browning of white adipose, 1st Author, 2015
- Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, 1st Author, 2013
- Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, 3rd Author, 2013
- 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor alpha, 1st Author, 2013
- Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine(790) -> methionine(790) mutant, 1st Author, 2012
- Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, 3rd Author, 2012
